Self-Treatment of Acute Migraine with Subcutaneous Sumatriptan Using an Auto-Injector Device: Comparison With Customary Treatment in An Open, Longitudinal Study

Cephalalgia ◽  
1994 ◽  
Vol 14 (1) ◽  
pp. 55-63 ◽  
Author(s):  
J Schoenen ◽  
J Bulcke ◽  
J Caekebeke ◽  
I Dehaene ◽  
J De Keyser ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Longitudinal Study ◽  
Treatment Recommendations ◽  
Acute Migraine ◽  
Duration Of Symptoms ◽  
Subcutaneous Sumatriptan ◽  
Auto Injector ◽  
Mild Headache ◽  
At Home

In a multicenter open longitudinal clinical trial where 479 patients suffering from migraine with or without aura were recruited, patients treated at home one to three migraine attacks with their customary treatment, and subsequently, over a 3-month period, one to three migraine attacks with (5 mg sumatriptan sc using an auto-injector. The headache response to customary treatment was 19% at 1 h and 30.5% at 2 h, and was not significantly different when only attacks treated “adequately” according to accepted treatment recommendations were considered: 16% at 1 h and 35% at 2 h. In contrast, 69% and 82% of patients treated with 6 mg sumatriptan sc had mild headache or no headache at 1 and 2 h respectively, regardless of migraine type or duration of symptoms prior to treatment. Other migraine symptoms (nausea, vomiting, photo- and phonophobia) were effectively treated with sumatriptan. Recurrence of migraine was observed in 31% of patients and was well controlled by a second injection of sumatriptan. It is concluded that 6 mg sumatriptan sc, self-administered using an auto-injector, is well tolerated and more effective than most currently used acute treatments for migraine in a population of severely affected patients consulting a neurologist.

The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial

Pain Practice ◽  
2014 ◽  
Vol 15 (8) ◽  
pp. 701-705 ◽  
Author(s):  
Hossein Moshtaghion ◽  
Najmeh Heiranizadeh ◽  
Abolghasem Rahimdel ◽  
Alireza Esmaeili ◽  
Hamidreza Hashemian ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Emergency Department ◽  
Acute Migraine ◽  
Migraine Headaches ◽  
Subcutaneous Sumatriptan ◽  
Double Blinded

An Open Study of Self-Administration of Subcutaneous Sumatriptan to Treat Successive Attacks of Acute Migraine

1994 ◽  
Vol 22 (4) ◽  
pp. 225-235 ◽  
Author(s):  
P Monteiro ◽  
Keyword(s):  
Adverse Event ◽  
Adverse Events ◽  
Open Study ◽  
Acute Treatment ◽  
Acute Migraine ◽  
Efficacy And Safety ◽  
Self Administration ◽  
Uncontrolled Study ◽  
Subcutaneous Sumatriptan ◽  
Auto Injector

The efficacy and safety of single doses of 6 mg sumatriptan, self-administered subcutaneously by patients using an auto-injector, for the acute treatment of up to three successive attacks of migraine was investigated in a multicentre, open, uncontrolled study in which 178 patients were enrolled. At attack 1, there was an improvement in headache (from severe or moderate to mild or no headache) in 74% of patients at 1 h, and in 82% at 2 h. The incidence of symptoms associated with migraine was decreased after sumatriptan injection. Nausea, vomiting and photo/phonophobia were reported by 72, 54, and 85% of patients, respectively, before the injection to treat attack 1, but by only 22, 12 and 27%, respectively, 2 h after the injection. Migraine recurred within 24 h in 27% of patients, but in 89% of patients was effectively treated with a further dose of 6 mg sumatriptan. Results for attacks 2 and 3 were similar. About 40% of patients experienced at least one adverse event; most of these were mild or moderate in intensity and were transient. It is concluded that 6 mg sumatriptan, self-administered using an auto-injector, is an effective and well tolerated treatment for migraine. Sumatriptan was as effective at attack 3 as at attack 1, and there was no evidence of a change in the incidence or the nature of adverse events with successive uses of the drug.

Moxibustion applied at home for non-vertex presentation: a multicentre randomised controlled clinical trial

2012 ◽  
Vol 4 ◽  
pp. 47
Author(s):  
Vas Jorge ◽  
Aranda-Regules José Manuel ◽  
Modesto Manuela ◽  
Barón Mercedes ◽  
Benítez-Parejo Nicolás ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Randomised Controlled Clinical Trial ◽  
Vertex Presentation ◽  
Randomised Controlled ◽  
At Home

Influence of treatment duration on the efficacy of at-home bleaching with daytime application: a randomized clinical trial

2018 ◽  
Vol 23 (8) ◽  
pp. 3229-3237 ◽  
Author(s):  
Iria L. Darriba ◽  
Paloma Cabirta Melón ◽  
Ana García Sartal ◽  
Ignacio Ríos Sousa ◽  
Víctor Alonso de la Peña
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Treatment Duration ◽  
At Home

scholarly journals Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19

2021 ◽  
Author(s):  
Paulo Sérgio da Silva Santos ◽  
Bernardo da Fonseca Orcina ◽  
Rafael Rahal Guaragna Machado ◽  
Fabiano Vieira Vilhena ◽  
Lucas Marques da Costa Alves ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Intensive Care ◽  
Hospital Stay ◽  
Length Of Hospital Stay ◽  
World Health ◽  
Care Hospital ◽  
Duration Of Symptoms ◽  
Intervention Protocol ◽  
Phthalocyanine Derivative

Abstract Background: The risk of contamination and dissemination by SARS-CoV-2 has a strong link with nasal, oral and pharyngeal cavities. Recently, our research group observed the promising performance of an anionic phthalocyanine derivative (APD) used in a mouthwash protocol without photoexcitation; this protocol improved the general clinical condition of patients infected with SARS-CoV-2. Methods: The present two-arm study evaluated in vitro the antiviral activity and cytotoxicity of APD. Additionally, a triple-blind randomized controlled trial was conducted with 41 hospitalized patients who tested positive for COVID-19. All the included patients received World Health Organization standard care hospital treatment (non-intensive care) plus active mouthwash (experimental group AM/n=20) or nonactive mouthwash (control group NAM/n=21). The adjunct mouthwash intervention protocol used in both groups consisted one-minute gargling/rinsing / 5 times/day until hospital discharge. Groups were compared considering age, number of comorbidities, duration of symptoms prior admission and length of hospital stay (LOS). The associations between group and sex, age range, presence of comorbidities, admission to Intensive care unit (ICU) and death were also evaluated. Results: The in vitro evaluation demonstrated that APD compound was highly effective for reduction of SARS-CoV-2 viral load in the 1.0 mg/mL (99.96%) to 0.125 mg/mL (92.65%) range without causing cytotoxicity. Regarding the clinical trial, the median LOS of the AM group was significantly shortened (4 days) compared with that of the NAM group (7 days) (p=0.0314). Additionally, gargling/rinsing with APD was very helpful in reducing the severity of symptoms (no ICU care was needed) compared to not gargling/rinsing with APD (28.6% of the patients in the NAM group needed ICU care, and 50% of this ICU subgroup passed way, p=0.0207). Conclusions: This study indicated that the mechanical action of the protocol involving mouthwash containing a compound with antiviral effects against SARS-CoV-2 may reduce the symptoms of the patients and the spread of infection. The use of APD in a mouthwash as an adjuvant the hospital COVID-19 treatment presented no contraindication and reduced the hospital stay period. Trial Registration: The clinical study was registered at REBEC - Brazilian Clinical Trial Register (RBR-58ftdj).

Evaluation of the genotoxic potential of different delivery methods of at-home bleaching gels: a single-blind, randomized clinical trial

2018 ◽  
Vol 23 (5) ◽  
pp. 2199-2206 ◽  
Author(s):  
Marcílio Jorge Fernandes Monteiro ◽  
Jéssica Bruna Corrêa Lindoso ◽  
Nikeila Chacon de Oliveira Conde ◽  
Luciana Mendonça da Silva ◽  
Alessandro D. Loguercio ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Delivery Methods ◽  
Genotoxic Potential ◽  
Bleaching Gels ◽  
Single Blind ◽  
At Home

A Different Point of View: The Evaluation of Motor Imagery Perspectives in Patients With Sensorimotor Impairments in A Longitudinal Study

2020 ◽  
Author(s):  
Szabina Gäumann ◽  
Rahel Sarah Gerber ◽  
Zorica Suica ◽  
Corina Schuster-Amft
Keyword(s):  
Clinical Trial ◽  
Longitudinal Study ◽  
Mental Rotation ◽  
Motor Imagery ◽  
Point Of View ◽  
Activity Level ◽  
Patient Specific ◽  
Activity Levels ◽  
Training Interventions ◽  
Mental Chronometry

Abstract BackgroundMotor imagery (MI) has been successfully applied in neurological rehabilitation. Little is known about the spontaneous selection of the MI perspectives in patients with sensorimotor impairments. What MI perspective is selected: internal (first- person view), or external (third-person view)? The aim was to evaluate the MI perspective preference in patients after stroke (STR), with Multiple Sclerosis (MS) or Parkinson’s disease (PD).MethodsIn a longitudinal study including four measurement sessions over two weeks, MI ability and MI perspective preference in both visual and kinaesthetic imagery modalities were assessed using the Kinaesthetic and Visual Imagery Questionnaire including 20 items (KVIQ-20), mental rotation, and mental chronometry. Additionally, patients' activity level was assessed. Descriptive statistical analyses were performed regarding different age- (≤44, 45-63, 64≤) and activity levels (inactive, partially active, active), and KVIQ-20 movement classifications (axial, proximal, distal, upper and lower limb).ResultsIn total, 55 in- and outpatients (25 SRT, 25 MS, 5 PD; 25 females; mean age 58±14 years) were included. At the first measurement session, the mean mental rotation score was 27±4.1 out of 32. For mental chronometry, a congruency ratio of 1.0±0.3 was determined. The KVIQ-20 scores for the visual and kinaesthetic subscales were 62.4±16.2 and 58.2±17.2. The internal MI perspective was favoured in 66.5% on the visual subscale and in 72.7% on the kinaesthetic subscale. The external perspective was preferred in 30.3% on the visual subscale and in 26.5% on the kinaesthetic subscale. Over the four measurement sessions, patients became more consistent in their MI perspective selection. MI perspective changes occurred mainly during imagination of shoulder, arm and neck movements. During imagination of foot and finger movements their MI perspective was more constant. Results showed a tendency to use an external perspective in patients older than 64 years and in patients with a descreasing physical activity level. Axial and proximal movements were commonly imagined using the external perspective. ConclusionIt is recommended to evaluate the spontaneous MI perspective selection to design patient-specific MI training interventions. Distal movements (foot, finger) may be an indicator when evaluating the consistency of the MI perspective in patients with sensorimotor impairments. Trial registrationThis is a research project involving persons other than a clinical trial according to the Human Research Act other than clinical (non-clinical trial). Registered: EKNZ 2015-172, 19. Mai 2015

Efficacy and Tolerability of Subcutaneous Sumatriptan for Acute Migraine: A Comparison Between Ethnic Groups

2001 ◽  
Vol 41 (9) ◽  
pp. 873-882 ◽  
Author(s):  
P. Burke‐Ramirez ◽  
M. Asgharnejad ◽  
C. Webster ◽  
R. Davis ◽  
A. Laurenza
Keyword(s):  
Ethnic Groups ◽  
Acute Migraine ◽  
Subcutaneous Sumatriptan
Sign in / Sign up

Export Citation Format

Share Document